Oxford Biomedica PLC Notice of Interim Results (2090V)
August 06 2015 - 2:01AM
UK Regulatory
TIDMOXB
RNS Number : 2090V
Oxford Biomedica PLC
06 August 2015
Oxford BioMedica: Notice of Interim Results
Results date: 27 August 2015
Oxford, UK - 6 August 2015: Oxford BioMedica plc (LSE: OXB),
("OXB" or "the Group") a leading gene and cell therapy group, will
be announcing its interim results for the six month months ended 30
June 2014 on Thursday 27 August 2015 at 7am BST.
An analyst briefing will be held at 9:30am BST on 27 August 2015
at the offices of Consilium Strategic Communications: 41 Lothbury,
EC2R 7HG. An audio replay will be made available shortly after the
presentation on the Group's website: www.oxfordbiomedica.co.uk.
-Ends-
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Media Enquiries: Tel: +44 (0)20
Mary-Jane Elliott/ Matthew Neal/ 3709 5700
Chris Welsh/ Laura Thornton
Consilium Strategic Communications
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Group's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Group has licenced products
and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is
available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk
.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLELFBEVFZBBV
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024